LIMINAL BIOSCIENCES INC (LMNL) Stock Overview
USA - NASDAQ:LMNL - CA53272L2021 - Common Stock
LMNL Key Statistics, Chart & Performance
The current stock price of LMNL is 8.5 USD. In the past month the price increased by 0.9%. In the past year, price increased by 102.38%.
LMNL Latest News, Press Relases and Analysis
LMNL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.53 | 402.76B | ||
| AMGN | AMGEN INC | 13.38 | 157.07B | ||
| GILD | GILEAD SCIENCES INC | 15.63 | 150.06B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.88 | 108.04B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.66 | 61.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.75B | ||
| ARGX | ARGENX SE - ADR | 88.74 | 50.32B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.02 | 34.14B | ||
| INSM | INSMED INC | N/A | 33.75B | ||
| NTRA | NATERA INC | N/A | 26.42B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.40B | ||
| BIIB | BIOGEN INC | 9.36 | 21.98B |
Related stock screener links
About LMNL
Company Profile
Liminal BioSciences, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Belleville, Ontario and currently employs 43 full-time employees. The company went IPO on 2019-07-05. The firm is focused on developing distinctive novel small molecule therapeutics for inflammatory, fibrotic and metabolic diseases using its drug discovery platform. The firm is developing Selective G-protein coupled receptor 84 (GPR84) Antagonist and Oxo-eicosanoid receptor 1 (OXER1) Antagonist. Its GPR84 is a pro-inflammatory target primarily expressed on cells associated with the immune system and its expression levels increase significantly during periods of inflammatory stress. Inhibition of GPR84 can inhibit neutrophil and macrophage migration and reduce cytokine release. GPR84 antagonist program is at the pre-clinical-stage. The OXER1 is a G protein-coupled receptor (GPCR) that is highly selective for 5-Oxo-eicosatetraenoic acid (5-oxo-ETE), a potent human eosinophil chemo-attractant. OXER1 antagonist program is in the pre-clinical-stage.
Company Info
LIMINAL BIOSCIENCES INC
231 Dundas Street East
Belleville ONTARIO H7V 4B4 CA
CEO: Bruce Pritchard
Employees: 43
Phone: 14507810115.0
LIMINAL BIOSCIENCES INC / LMNL FAQ
What does LIMINAL BIOSCIENCES INC do?
Liminal BioSciences, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Belleville, Ontario and currently employs 43 full-time employees. The company went IPO on 2019-07-05. The firm is focused on developing distinctive novel small molecule therapeutics for inflammatory, fibrotic and metabolic diseases using its drug discovery platform. The firm is developing Selective G-protein coupled receptor 84 (GPR84) Antagonist and Oxo-eicosanoid receptor 1 (OXER1) Antagonist. Its GPR84 is a pro-inflammatory target primarily expressed on cells associated with the immune system and its expression levels increase significantly during periods of inflammatory stress. Inhibition of GPR84 can inhibit neutrophil and macrophage migration and reduce cytokine release. GPR84 antagonist program is at the pre-clinical-stage. The OXER1 is a G protein-coupled receptor (GPCR) that is highly selective for 5-Oxo-eicosatetraenoic acid (5-oxo-ETE), a potent human eosinophil chemo-attractant. OXER1 antagonist program is in the pre-clinical-stage.
What is the stock price of LIMINAL BIOSCIENCES INC today?
The current stock price of LMNL is 8.5 USD. The price increased by 0.12% in the last trading session.
What is the dividend status of LIMINAL BIOSCIENCES INC?
LMNL does not pay a dividend.
What is the ChartMill rating of LIMINAL BIOSCIENCES INC stock?
LMNL has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the PE ratio for LMNL stock?
The PE ratio for LIMINAL BIOSCIENCES INC (LMNL) is 77.27. This is based on the reported non-GAAP earnings per share of 0.11 and the current share price of 8.5 USD.
Can you provide the market cap for LIMINAL BIOSCIENCES INC?
LIMINAL BIOSCIENCES INC (LMNL) has a market capitalization of 19.82M USD. This makes LMNL a Nano Cap stock.
What is the next earnings date for LMNL stock?
LIMINAL BIOSCIENCES INC (LMNL) will report earnings on 2023-11-07, after the market close.
LMNL Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to LMNL. When comparing the yearly performance of all stocks, LMNL is one of the better performing stocks in the market, outperforming 98.13% of all stocks.
LMNL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LMNL. Both the profitability and financial health of LMNL have multiple concerns.
LMNL Financial Highlights
Over the last trailing twelve months LMNL reported a non-GAAP Earnings per Share(EPS) of 0.11. The EPS decreased by -99.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 94.11% | ||
| ROA | 1.46% | ||
| ROE | 2.16% | ||
| Debt/Equity | 0.02 |
LMNL Forecast & Estimates
6 analysts have analysed LMNL and the average price target is 7.65 USD. This implies a price decrease of -10% is expected in the next year compared to the current price of 8.5.